CAP - CNBC

search results for

refine results

sort by

Date
Relevance

result type

Articles
Video

Wires
Press Releases

Advanced Micro leading the IQ100

I.Q. one hundred up more than twenty percent for one year it's an index tracking big cap companies that get most of their revenue from their own intellectual property today's leaders including A.M.D., Danaher, Honeywell, Cardinal Health and Amazon. For more go to CNBC.com/iq100

Source: CNBC.com

Reaction: Oil prices rallied as Nigeria agreed to cap crude production

Our live blog tracked market reaction as Nigeria voluntarily agreed to limit its oil output to 1.8 million barrels per day.

Source: CNBC.com

Trump lifted the cap on H-2B worker visas. Then his businesses asked for 76 of them.

Trump's golf clubs and resorts on the East Coast have long relied on hiring foreign seasonal workers, Vox reports.

Source: Vox

Small-cap stocks just hit an all-time high, but the upside may not last

Some strategists are forecasting downside for the index in the face of a weakening U.S. dollar.

Source: CNBC.com

Silver lining of China's 'Black Monday'

The sell-off in small-cap stocks in China on July 17 has led investors to focus on fundamentals, says Norman Chan of Oreana Private Wealth.

Source: CNBC.com

Trading Nation: Record high for small caps

Erin Gibbs, S&P GLobal, and Rich Ross, Evercore ISI, discuss the performance in small cap stocks with Melissa Lee.

Source: CNBC.com

Stryker leading the June 14th IQ100

The CNBC IQ100 up more than twenty percent for one year It's an index tracking big cap companies that get most of their revenue from their own intellectual property. Today's leaders include Stryker, Teradyne, Western Digital, Texas Instruments and CBS. For more go to CNBC.com/IQ100

Source: CNBC.com

Why I say small-cap biotechs are only for speculation

Jim Cramer admits he was too eager about the stock of Alder BioPharmaceuticals, which just took a huge hit.

Source: CNBC.com

Cramer: Mea culpa! This stock's action is why I say small-cap biotechs are only for speculation

Jim Cramer admits he was too eager about the stock of Alder BioPharmaceuticals, which just took a huge hit.

Source: CNBC.com

Cramer: Mea culpa! This stock's action is why I say small-cap biotechs are only for speculation

Jim Cramer admits he was too eager about the stock of Alder BioPharmaceuticals, which just took a huge hit.

Source: CNBC.com